Hepatotoxicity and cardiotoxicity continue to be responsible for drug attrition at all the stages of the drug development process1. Once a therapeutic has reached the market, these toxicities are the cause of black-box warnings, lawsuits, and withdrawal of approved drugs from the market.1,2 Consequently, identifying potential toxicities as early as possible can reduce the possibility of observing late stage failures, improve patient outcomes and save both time and valuable resources.
Contact us to learn more our toxicity testing services.
Contact us to learn more our toxicity testing services.
1. Uetrecht, J. (2008). Idiosyncratic drug reactions: past, present, and future. Chemical Research in Toxicology 21: 84-92.
2. Kaitin, KI. (2008)Obstacles and opportunities in new drug development. Clin Pharmacol Ther. 83(2): 210-2.